ClinicalTrials.gg
CompletedNCT01124175Updated Aug 19, 2024Results posted

Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions

A Phase 1 interventional study of Losartan and Cozaar® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare the rate and extent of absorption of losartan 100 mg tablets (test) versus Cozaar® (reference), administered as 1 * 100 mg tablet under fed conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non- female or male.
  • Non-smoker
  • 18 years or age and older.
  • Capable of consent.
  • Non-child-bearing potential female subject:

    • state: absence of menses for 12 months prior to drug administration.
    • Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at least 6 months prior to drug administration.

Exclusion criteria

Exclusion Criteria:

  • illness within 4 weeks prior to the administration of the study medication.
  • Clinically significant surgery within 4 weeks prior to the administration of the study medication.
  • Any clinically significant abnormality found during medical screening.
  • Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the subject from participating in the study.
  • Abnormal laboratory tests judged clinically significant.
  • Positive urine drug screen at screening.
  • abnormalities (clinically significant) or vital sign abnormalities at screening.
  • Subjects with greater than or equal to 30.0.
  • History of significant alcohol abuse within 6 months prior to the screening visit or any indication of the regular use of more than 14 units of alcohol per week (1 unit equals 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).
  • History of drug abuse of use of illegal drugs: use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], or crack) within 1 year prior to the screening visit.
  • History of allergic reactions to losartan or other related drugs.
  • History of allergic reactions to heparin.
  • Use of any drugs known to induce of inhibit drug metabolism within 30 days prior to administration of the study medication.
  • Use of an drug or participation in an investigational study within 30 days prior to administration of the study medication.
  • Clinically significant history or presence of any clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
  • Any clinically significant history or presence of neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.
  • Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic absorption.
  • Positive alcohol breath test at screening.
  • Subjects who have used tobacco in any form within the 90 days preceding study drug administration.
  • Any food allergy, intolerance, restriction, or special diet that could, in the opinion of the Medical Sub-Investigator, contraindicate the subject's participation in this study.
  • A depot injection or an implant of any drug within 3 months prior to administration of study medication.
  • Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood prior to administration of study medication as follows:

    • Less than 300 mL of whole blood within 30 days,
    • 300 mL to 500 mL of whole blood within 45 days, or
    • More than 500 mL of whole blood within 56 days prior to drug administration.
  • Consumption of food or beverages containing grapefruit within 7 days prior to administration of the study medication.
  • Clinically significant history or known hypotension or volume depletion.
  • Intolerance to venipuncture.
  • Clinically significant history or renal, hepatic, or cardiovascular disease, tuberculosis, epilepsy, asthma, diabetes, psychosis, or glaucoma will not be eligible for this study.
  • Subjects who are unable to understand or unwilling to sign the Form.
  • Additional exclusion criteria for females only:

    • Breast-feeding subjects.
    • Positive urine pregnancy test at screening (performed for all females).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Generic Test Product

    Losartan 100 mg Tablets

    Drug: Losartan

  • Active comparator
    Reference Listed Drug

    Cozaar® 100 mg Tablets

    Drug: Cozaar®

Interventions

  • 100 mg Tablets

  • 100 mg Tablets

    Also known as: Losartan (generic name)

06

What researchers measure

Primary outcomes

  1. Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)

    Bioequivalence based on Losartan Cmax.

    Time frame: Blood samples collected over a 24 hour period.

  2. AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Bioequivalence based on Losartan AUC0-t.

    Time frame: Blood samples collected over a 24 hour period.

  3. AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)

    Bioequivalence based on Losartan AUC0-inf.

    Time frame: Blood samples collected over a 24 hour period.

Secondary outcomes

  1. Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)

    Informational comparison of Cmax values for the metabolite Losartan Carboxy Acid.

    Time frame: Blood samples collected over a 24 hour period.

  2. AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Informational comparison of AUC0-t values for the metabolite Losartan Carboxy Acid.

    Time frame: Blood samples collected over a 24 hour period.

  3. AUC0-inf or Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Infinity)

    Informational comparison of AUC0-inf values for the metabolite Losartan Carboxy Acid.

    Time frame: Blood samples collected over a 24 hour period.

07

Results

Posted Jul 19, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneLosartan (Test) FirstCozaar® (Reference) First
Started4040
Completed4040
Not completed00
Washout of 7 Days
Participant flow — Washout of 7 Days
MilestoneLosartan (Test) FirstCozaar® (Reference) First
Started4040
Completed4038
Not completed02
Withdrew: Withdrawal by subject02
Second Intervention
Participant flow — Second Intervention
MilestoneLosartan (Test) FirstCozaar® (Reference) First
Started4038
Completed4038
Not completed00

Outcome measures

PrimaryCmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Losartan Cmax.

Time frame:
Blood samples collected over a 24 hour period.
Reported as:
Mean · ng/mL
Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)
ng/mLLosartan (Test)Cozaar® (Reference)
Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)407.66 ± 209.45360.82 ± 183.42
Statistical analysis
  • Losartan (Test) vs Cozaar® (Reference) · Ratio of the t/r geometric mean x 100: 111.95 · 90% CI 101.84 to 123.06Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on Losartan AUC0-t.

Time frame:
Blood samples collected over a 24 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
ng*h/mLLosartan (Test)Cozaar® (Reference)
AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)915.12 ± 271.70864.29 ± 260.73
Statistical analysis
  • Losartan (Test) vs Cozaar® (Reference) · Ratio of the t/r geometric mean x 100: 105.97 · 90% CI 103.61 to 108.39Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on Losartan AUC0-inf.

Time frame:
Blood samples collected over a 24 hour period.
Reported as:
Mean · ng*h/mL
AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)
ng*h/mLLosartan (Test)Cozaar® (Reference)
AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)926.82 ± 274.16877.73 ± 264.17
Statistical analysis
  • Losartan (Test) vs Cozaar® (Reference) · Ratio of the t/r geometric mean x 100: 105.67 · 90% CI 103.32 to 108.07Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
SecondaryCmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)

Informational comparison of Cmax values for the metabolite Losartan Carboxy Acid.

Time frame:
Blood samples collected over a 24 hour period.
Reported as:
Mean · ng/mL
Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)
ng/mLLosartan (Test)Cozaar® (Reference)
Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)587.80 ± 196.59560.83 ± 210.92
Statistical analysis
  • Losartan (Test) vs Cozaar® (Reference) · Ratio of the t/r geometric mean x 100: 105.97 · 90% CI 101.22 to 110.93Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
SecondaryAUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Informational comparison of AUC0-t values for the metabolite Losartan Carboxy Acid.

Time frame:
Blood samples collected over a 24 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
ng*h/mLLosartan (Test)Cozaar® (Reference)
AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)3556.41 ± 1032.483453.09 ± 1041.97
Statistical analysis
  • Losartan (Test) vs Cozaar® (Reference) · Ratio of the t/r geometric mean x 100: 103.07 · 90% CI 100.90 to 105.28Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
SecondaryAUC0-inf or Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Infinity)

Informational comparison of AUC0-inf values for the metabolite Losartan Carboxy Acid.

Time frame:
Blood samples collected over a 24 hour period.
Reported as:
Mean · ng*h/mL
AUC0-inf or Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Infinity)
ng*h/mLLosartan (Test)Cozaar® (Reference)
AUC0-inf or Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Infinity)3679.30 ± 1065.163607.01 ± 1119.74
Statistical analysis
  • Losartan (Test) vs Cozaar® (Reference) · Ratio of the t/r geometric mean x 100: 102.36 · 90% CI 100.41 to 104.34Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.

Adverse events

Collected over Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Losartan (Test)—0/80 (0%)5/80 (6.3%)
Cozaar® (Reference)—0/80 (0%)3/80 (3.8%)
Most frequent other events
Most frequent other events
EventLosartan (Test)Cozaar® (Reference)
Low Blood PressureGeneral disorders5/803/80

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Losartan (Test) FirstCozaar® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years373875
>=65 years325
Sex: Female, Male
Sex: Female, Male(Participants)Losartan (Test) FirstCozaar® (Reference) FirstTotal
Female132336
Male271744
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Losartan (Test) FirstCozaar® (Reference) FirstTotal
Black325
Caucasian363571
Hispanic134
Region of Enrollment
Region of Enrollment(participants)Losartan (Test) FirstCozaar® (Reference) FirstTotal
Canada404080
08

Study locations

1 site
  • Anapharm Inc.
    Sainte-Foy, Quebec G1V 2K8, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2010
First posted
May 14, 2010
Start
Oct 2003
Primary completionActual
Nov 2003
CompletionActual
Nov 2003
Results first posted
Jul 19, 2010
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01124175
First posted
May 14, 2010
Start date
Oct 2003
Primary completion
Nov 2003
Completion
Nov 2003
Results posted
Jul 19, 2010
Last update
Aug 19, 2024

Study contacts

Richard Larouche, MD
principal investigator · Anapharm

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion